Literature DB >> 15187136

Enhancer-mediated control of macrophage-specific arginase I expression.

Anne-Laure Pauleau1, Robert Rutschman, Roland Lang, Alessandra Pernis, Stephanie S Watowich, Peter J Murray.   

Abstract

Arginase I expression in the liver must remain constant throughout life to eliminate excess nitrogen via the urea cycle. In contrast, arginase I expression in macrophages is silent until signals from Th2 cytokines such as IL-4 and IL-13 are received and the mRNA is then induced four to five orders of magnitude. Arginase I is hypothesized to play a regulatory and potentially pathogenic role in diseases such as asthma, parasitic, bacterial, and worm infections by modulating NO levels and promoting fibrosis. We show that Th2-inducible arginase I expression in mouse macrophages is controlled by an enhancer that lies -3 kb from the basal promoter. PU.1, IL-4-induced STAT6, and C/EBPbeta assemble at the enhancer and await the effect of another STAT6-regulated protein(s) that must be synthesized de novo. Identification of a powerful extrahepatic regulatory enhancer for arginase I provides potential to manipulate arginase I activity in immune cells while sparing liver urea cycle function.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15187136     DOI: 10.4049/jimmunol.172.12.7565

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  108 in total

1.  Editorial: switching on arginase in M2 macrophages.

Authors:  Volker Briken; David M Mosser
Journal:  J Leukoc Biol       Date:  2011-11       Impact factor: 4.962

Review 2.  Macrophage plasticity and polarization: in vivo veritas.

Authors:  Antonio Sica; Alberto Mantovani
Journal:  J Clin Invest       Date:  2012-03-01       Impact factor: 14.808

3.  C/EBPβ regulates the M2 transcriptome in β-adrenergic-stimulated macrophages.

Authors:  Donald M Lamkin; Shreyesi Srivastava; Karen P Bradshaw; Jenna E Betz; Kevin B Muy; Anna M Wiese; Shelby K Yee; Rebecca M Waggoner; Jesusa M G Arevalo; Alexander J Yoon; Kym F Faull; Erica K Sloan; Steve W Cole
Journal:  Brain Behav Immun       Date:  2019-05-24       Impact factor: 7.217

4.  YAP/TAZ deficiency reprograms macrophage phenotype and improves infarct healing and cardiac function after myocardial infarction.

Authors:  Masum M Mia; Dasan Mary Cibi; Siti Aishah Binte Abdul Ghani; Weihua Song; Nicole Tee; Sujoy Ghosh; Junhao Mao; Eric N Olson; Manvendra K Singh
Journal:  PLoS Biol       Date:  2020-12-02       Impact factor: 8.029

5.  The primary mechanism of the IL-10-regulated antiinflammatory response is to selectively inhibit transcription.

Authors:  Peter J Murray
Journal:  Proc Natl Acad Sci U S A       Date:  2005-06-03       Impact factor: 11.205

6.  In vivo suppressive function of myeloid-derived suppressor cells is limited to the inflammatory site.

Authors:  Jessica M Haverkamp; Scott A Crist; Bennett D Elzey; Cansu Cimen; Timothy L Ratliff
Journal:  Eur J Immunol       Date:  2011-02-02       Impact factor: 5.532

7.  Retinoic acid promotes the development of Arg1-expressing dendritic cells for the regulation of T-cell differentiation.

Authors:  Jinsam Chang; Shankar Thangamani; Myung H Kim; Benjamin Ulrich; Sidney M Morris; Chang H Kim
Journal:  Eur J Immunol       Date:  2013-02-14       Impact factor: 5.532

8.  Schistosoma mansoni hemozoin modulates alternative activation of macrophages via specific suppression of Retnla expression and secretion.

Authors:  Martha Truscott; D Andrew Evans; Matt Gunn; Karl F Hoffmann
Journal:  Infect Immun       Date:  2012-10-22       Impact factor: 3.441

Review 9.  Targeting the progression of chronic kidney disease.

Authors:  Marta Ruiz-Ortega; Sandra Rayego-Mateos; Santiago Lamas; Alberto Ortiz; Raul R Rodrigues-Diez
Journal:  Nat Rev Nephrol       Date:  2020-02-14       Impact factor: 28.314

Review 10.  Monocyte subpopulations in angiogenesis.

Authors:  Heather J Dalton; Guillermo N Armaiz-Pena; Vianey Gonzalez-Villasana; Gabriel Lopez-Berestein; Menashe Bar-Eli; Anil K Sood
Journal:  Cancer Res       Date:  2014-02-20       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.